세계의 바이오의약품 자동화 시장(-2030년) : 컴포넌트별, 자동화 모드별, 기술별, 용도별, 최종 사용자별, 지역별 예측 및 분석

According to Stratistics MRC, the Global Automation in Biopharma Market is growing at a CAGR of 8.4% during the forecast period. Automation in biopharma is the use of advanced technologies and systems to streamline and optimize various processes in the production of biopharmaceuticals. This includes automating tasks such as cell culture, protein production, quality control, data analysis, and packaging. By integrating robotics, artificial intelligence, and machine learning, automation enhances efficiency, reduces human error, improves consistency, and accelerates time-to-market for new drugs. It plays a crucial role in ensuring regulatory compliance and cost-effective manufacturing in the biopharmaceutical industry.

Market Dynamics:

Driver:

Growing demand for personalized medicine

The growing demand for personalized medicine is driving the need for market. Personalized treatments require highly specific and scalable manufacturing processes to cater to individual patient needs, such as gene therapies and customized biologics. Automation facilitates the precise control of these complex processes, ensuring consistency, and efficiency. By enhancing production capabilities and reducing human error, automation enables biopharma companies to meet the increasing demand for tailored therapies, while ensuring high-quality standards.

Restraint:

Data security and privacy concerns

Data security and privacy concerns in biopharma automation can lead to significant risks, including unauthorized access to sensitive patient information, intellectual property theft, and regulatory violations. Breaches may result in reputational damage, costly fines, and loss of trust from stakeholders. Inadequate data protection can also hinder innovation and collaboration, as companies may be reluctant to share critical information, ultimately delaying drug development and affecting market competitiveness.

Opportunity:

Improved data quality and consistency

Improved data quality and consistency in the market enhances decision-making, regulatory compliance, and operational efficiency. By integrating advanced technologies such as AI and machine learning, companies can minimize human errors, streamline data collection, and ensure real-time data accuracy. This leads to more reliable processes, faster drug development, and optimized manufacturing, ultimately accelerating time-to-market and reducing costs while maintaining high standards of quality and safety.

Threat:

High initial investment costs

High initial investment costs in the market can be a significant barrier for smaller companies. The substantial upfront expenses for advanced technologies, equipment, and infrastructure may delay or prevent adoption. This can result in slower innovation, reduced competitiveness, and increased financial pressure. Smaller firms may struggle to secure funding, hindering their ability to scale operations, improve efficiency, and keep pace with larger industry players.

Covid-19 Impact:

The COVID-19 pandemic accelerated the adoption of the market, highlighting the need for faster, more efficient drug development and manufacturing processes. Automation helped streamline vaccine production, clinical trials, and supply chain management. However, the pandemic also disrupted global supply chains, leading to delays and challenges in deploying new technologies. Despite these hurdles, the crisis underscored automation's role in enhancing resilience and scalability in biopharma operations.

The automation software segment is expected to be the largest during the forecast period

The automation software segment is expected to account for the largest market share during the forecast period. It integrates technologies like AI, machine learning, and data analytics to improve efficiency, reduce errors, and ensure regulatory compliance. By automating repetitive tasks, these software solutions enhance accuracy in data collection, speed up production timelines, and support real-time monitoring. This ultimately leads to lower costs, faster time-to-market, and higher product quality in the biopharma industry.

The pharmaceutical companies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the pharmaceutical companies segment is predicted to witness the highest growth rate. By integrating automation tools like robotics, AI, and machine learning, they improve accuracy, reduce human error, and speed up production processes. These companies focus on optimizing supply chains, clinical trials, and quality control. Automation not only lowers operational costs but also accelerates innovation, ensuring faster time-to-market for critical therapies and treatments.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share driven by technological advancements and the need for more efficient drug production and development processes. With strong investments in AI, robotics, and data analytics, North American companies are optimizing manufacturing, enhancing quality control, and ensuring regulatory compliance. The region's focus on innovation, coupled with a robust healthcare infrastructure, positions it as a global leader in biopharma automation.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. The growing demand for biologics, biosimilars, and advanced therapies is pushing biopharmaceutical companies to adopt automation technologies to streamline production processes, improve consistency, and meet high production volumes. Additionally, the development of advanced technologies has enhanced automation systems, making them more accessible and adaptable to the biopharmaceutical industry.

Key players in the market

Some of the key players in Automation in Biopharma market include Thermo Fisher Scientific Inc., Siemens Healthineers AG, Danaher Corporation, GE HealthCare Technologies Inc., PerkinElmer, Inc., Tecan Group Ltd., Sartorius AG, Agilent Technologies, Inc., Hamilton Company, Bio-Rad Laboratories, Inc., Eppendorf AG, Bruker Corporation, Honeywell International Inc., Parker Hannifin Corporation, Rockwell Automation, Inc., Waters Corporation and Yokogawa Electric Corporation.

Key Developments:

In December 2024, Siemens Healthineers has concluded the acquisition from Novartis of Advanced Accelerator Applications Molecular Imaging, a European manufacturing and distribution network of diagnostic radiopharmaceuticals for positron emission tomography (PET) scans. The acquired company will be known as Advanced Accelerator Applications, a Siemens Healthineers company.

In June 2024, Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific(TM) KingFisher(TM) PlasmidPro Maxi Processor* (PlasmidPro), the only fully automated maxi-scale plasmid DNA (pDNA) purification system. PlasmidPro enables innovation at scale, providing complete automation across mini and maxi scale purification and delivering high-purity plasmid without manual column preparation and intervention.

Components Covered:

• Automation Hardware
• Automation Software
• Services Project Phase
• Services Operation Phase
• Analytics Automation
• Other Components

Mode of Automations Covered:

• Fully Automated Systems
• Semi-Automated Systems

Technologies Covered:

• Automation Technology
• Digitization Technology

Applications Covered:

• Research & Development
• Biomanufacturing
• Clinical Trials
• Quality Control & Assurance
• Diagnostics
• Other Applications

End Users Covered:

• Pharmaceutical Companies
• Biopharmaceutical Companies
• Contract Research Organizations (CROs)
• Academic and Research Institutions
• Laboratories
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Technology Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Automation in Biopharma Market, By Component

• 5.1 Introduction
• 5.2 Automation Hardware
• 5.3 Automation Software
• 5.4 Services Project Phase
• 5.5 Services Operation Phase
• 5.6 Analytics Automation
• 5.7 Other Components

6 Global Automation in Biopharma Market, By Mode of Automation

• 6.1 Introduction
• 6.2 Fully Automated Systems
• 6.3 Semi-Automated Systems

7 Global Automation in Biopharma Market, By Technology

• 7.1 Introduction
• 7.2 Automation Technology
  • 7.2.1 Process Automation
  • 7.2.2 Laboratory Automation
  • 7.2.3 Robotics and Artificial Intelligence
  • 7.2.4 Control Systems
  • 7.2.5 Programmable Logic Controllers (PLCs)
• 7.3 Digitization Technology
  • 7.3.1 Data Analytics and Visualization
  • 7.3.2 Electronic Lab Notebooks (ELN)
  • 7.3.3 Cloud Computing
  • 7.3.4 Internet of Things (IoT)
  • 7.3.5 Digital Twin Technology

8 Global Automation in Biopharma Market, By Application

• 8.1 Introduction
• 8.2 Research & Development
  • 8.2.1 Drug Discovery
  • 8.2.2 Genomics and Proteomics
• 8.3 Biomanufacturing
  • 8.3.1 Upstream Processing
  • 8.3.2 Downstream Processing
• 8.4 Clinical Trials
• 8.5 Quality Control & Assurance
• 8.6 Diagnostics
• 8.7 Other Applications

9 Global Automation in Biopharma Market, By End User

• 9.1 Introduction
• 9.2 Pharmaceutical Companies
• 9.3 Biopharmaceutical Companies
• 9.4 Contract Research Organizations (CROs)
• 9.5 Academic and Research Institutions
• 9.6 Diagnostic Laboratories
• 9.7 Other End Users

10 Global Automation in Biopharma Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Thermo Fisher Scientific Inc.
• 12.2 Siemens Healthineers AG
• 12.3 Danaher Corporation
• 12.4 GE HealthCare Technologies Inc.
• 12.5 PerkinElmer, Inc.
• 12.6 Tecan Group Ltd.
• 12.7 Sartorius AG
• 12.8 Agilent Technologies, Inc.
• 12.9 Hamilton Company
• 12.10 Bio-Rad Laboratories, Inc.
• 12.11 Eppendorf AG
• 12.12 Bruker Corporation
• 12.13 Honeywell International Inc.
• 12.14 Parker Hannifin Corporation
• 12.15 Rockwell Automation, Inc.
• 12.16 Waters Corporation
• 12.17 Yokogawa Electric Corporation